Genmab (GMAB) Stock Forecast & Price Target

Compare

767 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

GMAB Analyst Ratings

Moderate Buy

5 Buy

2 Hold

0 Sell

Based on 7 analysts giving stock ratings to

Genmab

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

GMAB Stock 12 Month Forecast

Average Price Target

$36.10

▲(9.29% Upside)

Based on 7 Wall Street analysts offering 12 month price targets for Genmab in the last 3 months. The average price target is $36.10 with a high forecast of $45.00 and a low forecast of $26.00. The average price target represents a 9.29% change from the last price of $33.03.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"17":"$17","46":"$46","24.25":"$24.3","31.5":"$31.5","38.75":"$38.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$45.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":36.1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$36.10</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$26.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[17,24.25,31.5,38.75,46],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.27,34.1723076923077,35.074615384615385,35.97692307692308,36.87923076923077,37.78153846153846,38.683846153846154,39.58615384615385,40.488461538461536,41.39076923076923,42.293076923076924,43.19538461538461,44.097692307692306,{"y":45,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.27,33.48769230769231,33.70538461538462,33.92307692307693,34.14076923076923,34.35846153846154,34.57615384615385,34.793846153846154,35.011538461538464,35.229230769230774,35.44692307692308,35.66461538461539,35.88230769230769,{"y":36.1,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.27,32.71076923076923,32.151538461538465,31.592307692307696,31.033076923076926,30.473846153846157,29.914615384615388,29.355384615384615,28.79615384615385,28.236923076923077,27.67769230769231,27.11846153846154,26.55923076923077,{"y":26,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":19.67,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.68,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.66,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.93,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.77,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.74,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.78,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.89,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.77,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.61,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.39,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.8,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.27,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$45.00

Average Price Target$36.10

Lowest Price Target$26.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Ram Selvaraju

H.C. Wainwright

$39

Buy

18.07%

Upside

Reiterated

01/28/26

Analysts Offer Insights on Healthcare Companies: Roche Holding AG (Other OTC: RHHVF) and Genmab (NASDAQ: GMAB)

Asthika Goonewardene

Truist Financial

Buy

―

Reiterated

01/20/26

Analysts' Top Healthcare Picks: Fortrea Holdings Inc. (FTRE), Genmab (GMAB)

Charlie Haywood

Bank of America Securities

$34.7→$38.5

Buy

16.56%

Upside

Reiterated

01/19/26

Genmab price target raised to $38.50 from $34.70 at BofAGenmab price target raised to $38.50 from $34.70 at BofA

Michael Schmidt

Guggenheim

$45

Buy

36.24%

Upside

Reiterated

01/16/26

Analysts Are Bullish on These Healthcare Stocks: Genmab (GMAB), Glaukos (GKOS)

Matt Phipps

William Blair

Buy

―

Reiterated

01/16/26

Genmab: Limited Epkinly Approval Risk and High-Value 2026 Pipeline Catalysts Support Buy Rating

Rajan Sharma

Goldman Sachs

$26

Hold

-21.28%

Downside

Reiterated

12/15/25

Genmab's Mixed Prospects: Hold Rating Amid Promising Pipeline and Uncertainties

Yaron Werber

TD Cowen

$32

Hold

-3.12%

Downside

Reiterated

11/07/25

Analysts Offer Insights on Healthcare Companies: Genmab (NASDAQ: GMAB), Aziyo Biologics (NASDAQ: ELUT) and Ironwood Pharma (NASDAQ: IRWD)

Jonathan Chang

Leerink Partners

$34→$39

Buy

18.07%

Upside

Reiterated

10/13/25

Leerink Partners Reaffirms Their Buy Rating on Genmab (GMAB)

Justin Smith

Bernstein

Sell

―

Reiterated

09/08/25

Bernstein Remains a Sell on Genmab (GMAB)

Vikram Purohit

Morgan Stanley

$25

Hold

-24.31%

Downside

Reiterated

07/02/25

Morgan Stanley Keeps Their Hold Rating on Genmab (GMAB)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Ram Selvaraju

H.C. Wainwright

$39

Buy

18.07%

Upside

Reiterated

01/28/26

Analysts Offer Insights on Healthcare Companies: Roche Holding AG (Other OTC: RHHVF) and Genmab (NASDAQ: GMAB)

Asthika Goonewardene

Truist Financial

Buy

―

Reiterated

01/20/26

Analysts' Top Healthcare Picks: Fortrea Holdings Inc. (FTRE), Genmab (GMAB)

Charlie Haywood

Bank of America Securities

$34.7→$38.5

Buy

16.56%

Upside

Reiterated

01/19/26

Genmab price target raised to $38.50 from $34.70 at BofAGenmab price target raised to $38.50 from $34.70 at BofA

Michael Schmidt

Guggenheim

$45

Buy

36.24%

Upside

Reiterated

01/16/26

Analysts Are Bullish on These Healthcare Stocks: Genmab (GMAB), Glaukos (GKOS)

Matt Phipps

William Blair

Buy

―

Reiterated

01/16/26

Genmab: Limited Epkinly Approval Risk and High-Value 2026 Pipeline Catalysts Support Buy Rating

Rajan Sharma

Goldman Sachs

$26

Hold

-21.28%

Downside

Reiterated

12/15/25

Genmab's Mixed Prospects: Hold Rating Amid Promising Pipeline and Uncertainties

Yaron Werber

TD Cowen

$32

Hold

-3.12%

Downside

Reiterated

11/07/25

Analysts Offer Insights on Healthcare Companies: Genmab (NASDAQ: GMAB), Aziyo Biologics (NASDAQ: ELUT) and Ironwood Pharma (NASDAQ: IRWD)

Jonathan Chang

Leerink Partners

$34→$39

Buy

18.07%

Upside

Reiterated

10/13/25

Leerink Partners Reaffirms Their Buy Rating on Genmab (GMAB)

Justin Smith

Bernstein

Sell

―

Reiterated

09/08/25

Bernstein Remains a Sell on Genmab (GMAB)

Vikram Purohit

Morgan Stanley

$25

Hold

-24.31%

Downside

Reiterated

07/02/25

Morgan Stanley Keeps Their Hold Rating on Genmab (GMAB)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Genmab

3 Months

xxx

Success Rate

8/8 ratings generated profit

Average Return

+12.96%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +12.96% per trade.

1 Year

Jonathan ChangLeerink Partners

Success Rate

7/7 ratings generated profit

Average Return

+53.36%

a rating ―

Copying Jonathan Chang's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +53.36% per trade.

2 Years

xxx

Success Rate

7/7 ratings generated profit

Average Return

+53.36%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +53.36% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GMAB Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, GMAB has received 12 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. GMAB average Analyst price target in the past 3 months is 36.10.

Each month's total comprises the sum of three months' worth of ratings.

GMAB Financial Forecast

GMAB Earnings Forecast

Currently, no earnings data available.

GMAB Sales Forecast

Currently, no sales data available.

GMAB Stock Forecast FAQ

What is GMAB’s average 12-month price target, according to analysts?

Based on analyst ratings, Genmab A/S’s 12-month average price target is 36.10.

What is GMAB’s upside potential, based on the analysts’ average price target?

Genmab A/S has 9.29% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is GMAB a Buy, Sell or Hold?

Genmab A/S has a consensus rating of Moderate Buy which is based on 5 buy ratings, 2 hold ratings and 0 sell ratings.

What is Genmab A/S’s price target?

The average price target for Genmab A/S is 36.10. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $45.00 ,the lowest forecast is $26.00. The average price target represents 9.29% Increase from the current price of $33.03.

What do analysts say about Genmab A/S?

Genmab A/S’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of GMAB?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Genmab (GMAB) Stock Forecast & Price Target

GMAB Analyst Ratings

GMAB Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Genmab

GMAB Analyst Recommendation Trends

GMAB Financial Forecast

GMAB Earnings Forecast

GMAB Sales Forecast

GMAB Stock Forecast FAQ

Detailed List of Analyst Forecasts